In smaller single-center studies, patients with
cirrhosis are at a high readmission risk, but a multicenter perspective study is lacking. We evaluated the determinants of 3-month readmissions among inpatients with
cirrhosis using the prospective 14-center North American Consortium for the Study of
End-Stage Liver Disease cohort. Patients with
cirrhosis hospitalized for nonelective indications provided consent and were followed for 3 months postdischarge. The number of 3-month readmissions and their determinants on index admission and discharge were calculated. We used multivariable logistic regression for all readmissions and for
hepatic encephalopathy (HE), renal/metabolic, and
infection-related readmissions. A score was developed using admission/discharge variables for the total sample, which was validated on a random half of the total population. Of the 1353 patients enrolled, 1177 were eligible on discharge and 1013 had 3-month outcomes. Readmissions occurred in 53% (n = 535; 316 with one, 219 with two or more), with consistent rates across sites. The leading causes were liver-related (n = 333; HE, renal/metabolic, and
infections). Patients with
cirrhosis and with worse Model for
End-Stage Liver Disease score or diabetes, those taking prophylactic
antibiotics, and those with prior HE were more likely to be readmitted. The admission model included Model for
End-Stage Liver Disease and diabetes (c-statistic = 0.64, after split-validation 0.65). The discharge model included Model for
End-Stage Liver Disease,
proton pump inhibitor use, and lower
length of stay (c-statistic = 0.65, after split-validation 0.70). Thirty percent of readmissions could not be predicted. Patients with liver-related readmissions consistently had index-stay
nosocomial infections as a predictor for HE, renal/metabolic, and
infection-associated readmissions (odds ratio = 1.9-3.0).
CONCLUSIONS: